Prognostic significance of aberrant CD5 expression in B-cell leukemia

  • Kaveh Jaseb Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Daryush Purrahman Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Saeid Shahrabi Department of Biochemistry and Hematology, Faculty of Medicine, Semnan University Of Medical Sciences, Semnan, Iran, Islamic Republic of.
  • Majid Ghanavat Child Growth & Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic Republic of.
  • Hadi Rezaeean Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.
  • Najmaldin Saki | Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Islamic Republic of.


Aberrant expression of CD5 (as a T-cell marker) is seen in some leukemia and lymphoma of B lineage origin. Given that the signaling resulting from the expression of this marker plays an essential role in the development of leukemia and lymphoma, evaluating the expression of this marker is of paramount importance. Therefore, our goal in this study was to investigate the prognostic importance of CD5 expression in B-cell leukemia and lymphoma. We evaluate CD5 expression in normal and leukemic B-cells by identifying relevant literature through a PubMed search (1998-2018) of English language papers using the terms: ‘CD5,’ ‘B-cell,’ ‘Leukemia,’ and ‘Lymphoma.’ We are doing this thorough comparison of results from CD5 positive and negative cases to make a correct decision about prognostic importance of CD5 expression in these malignancies. In a number of B-cell malignancies, CD5 is expressed in varying degrees. Due to the different origins and characteristics of these malignancies, the results of CD5 expression evaluations are heterogeneous and impossible to generalize. However, CD5 expression is sometimes associated with clinicopathologic findings, more invasive clinical course, and even resistance to treatment (specifically in DLBCL) among CD5- positive patients, which appears to be a function of CD5 signaling and its downstream factors such as STAT3. Depending on the type of malignancy, CD5 expression is associated with good or bad prognosis, which can be used as an auxiliary prognostic factor to assess the clinical course of B-cell malignancies. Moreover, the difference in expression levels of CD5 in a variety of B-cell malignancies allows for differential diagnosis of these malignancies, which can be helpful when diagnosis is difficult.



PlumX Metrics


Download data is not yet available.


Dalloul A. CD5: a safeguard against autoimmunity and a shield for cancer cells. Autoimmun Rev 2009;8:349-53. DOI:

Thakral B, Medeiros LJ, Desai P, et al. Prognostic impact of CD5 expression in diffuse large B‐cell lymphoma in patients treated with rituximab‐EPOCH. Eur J Haematol 2017;98:415-21. DOI:

Consuegra-Fernández M, Aranda F, Simões I, et al. CD5 as a target for immune-based therapies. Crit Rev Immunol 2015;2:35. DOI:

Zhang C, Xin H, Zhang W, et al. CD5 binds to interleukin-6 and induces a feed-forward loop with the transcription factor STAT3 in B cells to promote cancer. Immun 2016;44:913-23. DOI:

Mageed RA, Garaud S, Taher TE, et al. CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte. Autoimmun Rev 2012;11:795-8. DOI:

Garaud S, Taher TE, Debant M, et al. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. Cell Mol Immunol 2016 [Epub ahead of print]. DOI:

Xu-Monette ZY, Tu M, Jabbar KJ, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries. Oncotarget 2015;6:5615. DOI:

Rozovski U, Harris DM, Li P, et al. Constitutive phosphorylation of STAT3 by the CK2-BLNK-CD5. Complex 2017;15:610-8. DOI:

Mutreja D, Pati HP, Bansal D, et al. Aberrant immunophenotypic expression of CD5 in a case of B acute lymphoblastic leukemia: a case report. Indian J Hematol Blood Transf 2014;30:212-4. DOI:

Perez-Chacon G, Vargas JA, Jorda J, et al. CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC 2007;31:183-93. DOI:

Tibaldi E, Brunati A, Zonta F, et al. Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell. Chron Lymphocyt Leuk Cells 2011;25:1768.

Alhakeem SS, Sindhava VJ, McKenna MK, et al. Role of B cell receptor signaling in IL‐10 production by normal and malignant B-1 cells. 2015;1362:239-49. DOI:

Perez-Chacon G, Vargas JA, Jorda J, et al. CD5 does not regulate the signaling triggered through BCR in B cells from a subset of B-CLL patients. Leuk Lymph 2007;48:147-57. DOI:

Garaud S, Morva A, Lemoine S, et al. CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 2011;186:4835-44. DOI:

Gary-Gouy H, Sainz-Perez A, Marteau J-B, et al. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol 2007;179:4335-44. DOI:

Laurenti L, Vannata B, Innocenti I, et al. The use of monoclonal antibodies in the treatment of autoimmune complications of chronic lymphocytic leukemia. Med J Hematol Infect Dis 2013;5:1. DOI:

Murphy M, Hoss D. Cutaneous involvement by CD5-negative chronic lymphocytic leukemia (CLL)-aberrant phenotype or false negativity? Implications for immunohistochemical testing on paraffin‐embedded skin specimens. J Cutan Pathol 2011;38:73-5. DOI:

Yavasoglu I, Sargin G, Kadikoylu G, et al. The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro. Med Oncol 2013;30:603. DOI:

Efstathiou S, Tsioulos D, Zacharos I, et al. The prognostic role of CD5 negativity in B-cell chronic lymphocytic leukaemia: a case-control study. Leukemia 2002;32:209-18.

Romano C, Sellitto A, Chiurazzi F, et al. Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. Leukemia 2015;101:67-74.

Hercher C, Robain M, Davi F, et al. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms: the Groupe Français d'Hématologie Cellulaire. Leukemia 2001;42:981-7.

Kar R, Kumar R, Tyagi SJTJoH. De-novo CD5+ B-prolymphocyte leukemia (PLL) presenting at younger age with favourable outcome. Leuk Lymph 2008;25:3.

Ruchlemer R, Parry‐Jones N, Brito‐Babapulle V, Attolico I, Wotherspoon AC, Matutes E, et al. B‐prolymphocytic leukaemia with t (11; 14) revisited: a splenomegalic form of mantle cell lymphoma evolving with leukaemia. 2004;125:330-6. DOI:

Wohlschlaeger C, Lange K, Merz H, Feller A. Aberrant immunophenotypes of mantle cell lymphomas. Leuk Lymph 2003;44:269-73. DOI:

Elyamany G, Alzahrani AM, Al Mussaed E, et al. De Novo CD5 Negative Blastic Mantle Cell Lymphoma Presented with Massive Bone Marrow Necrosis without Adenopathy or Organomegaly. 2015;2015. DOI:

Miao Y, Lin P, Wang W, et al. CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma. Am J Clin Pathol 2016;146:747-52. DOI:

Yamada T, Goto N, Tsurumi H, et al. Mantle cell lymphoma with a unique pattern of CD5 expression: a case report with review of the literatures. Med Mol Morphol 2014;47:169-75. DOI:

Todorovic M, Balint B, Andjelic B, et al. Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study. Med Oncol 2012;29:2212-9. DOI:

Chuang W-Y, Chang H, Shih L-Y, Wang P-N, Chang Y-S, Lin T-L, et al. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma. Virchows Archiv 2015;467:571-82. DOI:

Taniguchi M, Oka K, Hiasa A, et al. De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation. Blood 1998;91:1145-51. DOI:

Zhang X, Sun M, Zhang L, Shao H. Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review. Int J Clin Exper Pathol 2013;6:985.

Ennishi D, Takeuchi K, Yokoyama M, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol 2008;19:1921-6. DOI:

Mayson E, Saverimuttu J, Cartwright K. CD5-positive follicular lymphoma: prognostic significance of this aberrant marker? Intern Med J 2014;44:417-22. DOI:

Barry TS, Jaffe ES, Kingma DW, et al. CD5+ follicular lymphoma: a clinicopathologic study of three cases. Am J Clin Pathol 2002;118:589-98. DOI:

Li Y, Hu S, Zuo Z, et al. CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. Modern Pathology 2015;28:787-98. DOI:

Sonoki T, Ishihara S, Uneda S, et al. Aggressive CD5-positive B-cell lymphoma after remission of CD5-negative follicular lymphoma with distinct immunoglobulin heavy chain rearrangement and translocation. Int J Hematol 2008;88:299-303. DOI:

Miyoshi H, Sato K, Yoshida M, et al. CD5‐positive follicular lymphoma characterized by CD25, MUM1, low frequency of t (14; 18) and poor prognosis. Pathol Int 2014;64:95-103. DOI:

Raya J, Ruano J, Bosch J, et al. Splenic marginal zone lymphoma-a clinicopathological study in a series of 16 patients. Hematology 2008;13:276-81. DOI:

Gimeno E, Salido M, Solé F, et al. CD5 negative and CD5 positive splenic marginal B-cell lymphomas have differential cytogenetic patterns. Leuk Res 2005;29:98. DOI:

Giannouli S, Paterakis G, Ziakas PD, et al. Splenic marginal zone lymphomas with peripheral CD5 expression. Haematologica 2004;89:113-4.

Salido M, Baró C, Oscier D, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010;2:267476. DOI:

Kojima M, Sato E, Oshimi K, et al. Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation; clinical, flow cytometry, and histopathological findings of 11 cases. J Clin Exp Hematopathol 2010;50:107-12. DOI:

Baseggio L, Traverse-Glehen A, Petinataud F, et al. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 2010;95:604-12. DOI:

Peterson MR, Noskoviak KJ, Newbury R. CD5-positive B-cell acute lymphoblastic leukemia. Pediatr Develop Pathol 2007;10:41-5. DOI:

Hussein S, Gill KZ, Sireci AN, et al. Aberrant T‐cell antigen expression in B lymphoblastic leukaemia. Br J Haematol 2011;155:449-56. DOI:

Ahmed D, Ahmed TA, Ahmed S, et al. CD5-positive acute lymphoblastic leukemia. J Coll Physicians Surg Pak 2008;18:310-1.

Challagundla P, Jorgensen JL, Kanagal-Shamanna R, et al. Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms. Archiv Pathol Lab Med 2014;138:903-9. DOI:

Huang PY-H, Kohnke P, Belov L, et al. Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. J Pharm Pharm Sci 2013;16:231-7. DOI:

CD5, leukemia, lymphoma, prognosis.
  • Abstract views: 3594

  • PDF: 640
  • HTML: 364
How to Cite
Jaseb, K., Purrahman, D., Shahrabi, S., Ghanavat, M., Rezaeean, H., & Saki, N. (2019). Prognostic significance of aberrant CD5 expression in B-cell leukemia. Oncology Reviews, 13(1).

Most read articles by the same author(s)